Portal de investigación
EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology
Autores de CIPF
Participantes ajenos a CIPF
- Brennecke, P
- Rasina, D
- Aubi, O
- Herzog, K
- Landskron, J
- Cautain, B
- Quintana, J
- Mestres, J
- Stechmann, B
- Ellinger, B
- Brea, J
- Kolanowski, JL
- Pilarski, R
- Laraia, L
- Nami, F
- Zielenkiewicz, P
- Paruch, K
- Hansen, E
- von Kries, JP
- Neuenschwander, M
- Specker, E
- Bartunek, P
- Simova, S
- Lesnikowski, Z
- Krauss, S
- Lehtio, L
- Bilitewski, U
- Bronstrup, M
- Tasken, K
- Jirgensons, A
- Lickert, H
- Clausen, MH
- Andersen, JH
- Genilloud, O
- Nazare, M
- Fecke, W
- Gribbon, P
Grupos de Investigación
Abstract
Compound screening in biological assays and subsequent optimization of hits is indispensable for the development of new molecular research tools and drug candidates. To facilitate such discoveries, the European Research Infrastructure EU-OPENSCREEN was founded recently with the support of its member countries and the European Commission. Its distributed character harnesses complementary knowledge, expertise, and instrumentation in the discipline of chemical biology from 20 European partners, and its open working model ensures that academia and industry can readily access EU-OPENSCREEN's compound collection, equipment, and generated data. To demonstrate the power of this collaborative approach, this perspective article highlights recent projects from EU-OPENSCREEN partner institutions. These studies yielded (1) 2-aminoquinazolin-4(3H)-ones as potential lead structures for new antimalarial drugs, (2) a novel lipodepsipeptide specifically inducing apoptosis in cells deficient for the pVHL tumor suppressor, (3) small-molecule-based ROCK inhibitors that induce definitive endoderm formation and can potentially be used for regenerative medicine, (4) potential pharmacological chaperones for inborn errors of metabolism and a familiar form of acute myeloid leukemia (AML), and (5) novel tankyrase inhibitors that entered a lead-to-candidate program. Collectively, these findings highlight the benefits of small-molecule screening, the plethora of assay designs, and the close connection between screening and medicinal chemistry within EU-OPENSCREEN.
Datos de la publicación
- ISSN/ISSNe:
- 2472-5552, 2472-5560
- Tipo:
- Article
- Páginas:
- 398-413
- PubMed:
- 30616481
SLAS Discovery SAGE PUBLICATIONS INC
Citas Recibidas en Web of Science: 19
Documentos
- No hay documentos
Filiaciones
Keywords
- chemical biology; screening; medicinal chemistry; open access; compound library
Proyectos asociados
Towards the design of Personalised Polymer-based Combiantion Nanomedicines for Advanced Stage Breast Cancer Patients
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2015
Exploiting Protein Complexes that induce Cell-death
Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD
COMMISSION OF EUROPEAN COMMUNITIES . 2016
Ensuring long-term sustainability of excellence in chemical biology within Europe and beyond
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2019
Off the self polypeptide based inmmunotherapy for Advanced Melanoma Treatment
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2019
Red de Transtornos Adictivos
Investigador Principal: CONSUELO GUERRI SIRERA
INSTITUTO DE SALUD CARLOS III . 2017
Polímeros Terapéuticos diseñados para cruzar la Barrera Hematoencefálica para el tratamiento de desordenes neurodegenerativos-Explorando la Ruta Intranasal.
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE ECON. Y COMPET. . 2016
Combinatory treatment of Neural precursor cells and a new nanoconjugate of Fasudil for the clinical application in Acute Spinal Cord Injury
Investigador Principal: MARIA JESUS VICENT DOCON
FUNDACION LA MARATO DE TV3 . 2018
Bases moleculares de las alteraciones neurológicas (cognitivas y motoras) en hiperamonemia y encefalopatía hepática. Implicaciones terapéuticas
Investigador Principal: VICENTE FELIPO ORTS
MINISTERIO DE ECON. Y COMPET. . 2018
Descifrando y modulando el interactoma transmembrana de las proteínas Bcl-2 como diana antitumoral
Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD
MINISTERIO DE ECON. Y COMPET. . 2018
Mecanismos moleculares y cerebrales de las alteraciones cognitivas y motoras en hiperamonemia y encefalopatía hepática. Implicaciones terapeúticas y diagnósticas
Investigador Principal: VICENTE FELIPO ORTS
CONSELLERIA DE EDUCACION . 2018
Organoides tumorales de cáncer de pulmón como modelo personalizado para estudiar la biología del tumor y la respuesta a fármaco
Investigador Principal: CAROLINA GANDÍA VENTURA
CONSELLERIA DE EDUCACION . 2018
RTC-2017-6600-1 Desarrollo de una plataforma de terapia génica para enfermedades genéticas renales
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2018
Desarrollo de terapias tópicas basadas en sistemas de transporte polipeptídicos
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2018
Validación farmacológica in vivo de nanofármacos inhibidores de ROCK2 en cáncer de mama metastásico y lesión medular
Investigador Principal: M VICTORIA MORENO MANZANO
AGENCIA VALENCIANA DE INNOVACIÓN . 2019
MEMBDEATH: Muerte celular y membranas: un nuevo nicho en la lucha contra el cáncer. Colab con la UV, no recibimos financiación
Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD
CONSELLERIA DE EDUCACION . 2019